[go: up one dir, main page]

NO20052655L - Sammensmeltede heterocykliske forbindelser - Google Patents

Sammensmeltede heterocykliske forbindelser

Info

Publication number
NO20052655L
NO20052655L NO20052655A NO20052655A NO20052655L NO 20052655 L NO20052655 L NO 20052655L NO 20052655 A NO20052655 A NO 20052655A NO 20052655 A NO20052655 A NO 20052655A NO 20052655 L NO20052655 L NO 20052655L
Authority
NO
Norway
Prior art keywords
merged
heterocyclic compounds
treatment
disorders
useful
Prior art date
Application number
NO20052655A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052655D0 (no
Inventor
Juan C Jaen
Xiaoqi Chen
Pingchen Fan
Leping Li
Xi Chen
Jeffrey T Mihalic
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20052655D0 publication Critical patent/NO20052655D0/no
Publication of NO20052655L publication Critical patent/NO20052655L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052655A 2002-11-06 2005-06-02 Sammensmeltede heterocykliske forbindelser NO20052655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42445602P 2002-11-06 2002-11-06
PCT/US2003/035543 WO2004043958A1 (fr) 2002-11-06 2003-11-06 Composes heterocycliques condenses

Publications (2)

Publication Number Publication Date
NO20052655D0 NO20052655D0 (no) 2005-06-02
NO20052655L true NO20052655L (no) 2005-07-26

Family

ID=32312811

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052655A NO20052655L (no) 2002-11-06 2005-06-02 Sammensmeltede heterocykliske forbindelser

Country Status (16)

Country Link
US (2) US7253179B2 (fr)
EP (1) EP1562943A1 (fr)
JP (1) JP4547266B2 (fr)
KR (1) KR20050103184A (fr)
CN (2) CN101134757A (fr)
AU (1) AU2003285160B2 (fr)
BR (1) BR0316070A (fr)
CA (1) CA2505372A1 (fr)
EA (1) EA009421B1 (fr)
IS (1) IS7833A (fr)
MX (1) MXPA05004739A (fr)
NO (1) NO20052655L (fr)
NZ (1) NZ540328A (fr)
PL (1) PL376659A1 (fr)
WO (1) WO2004043958A1 (fr)
ZA (1) ZA200503654B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
AU2003285160B2 (en) * 2002-11-06 2009-06-04 Amgen Inc. Fused heterocyclic compounds
US7727998B2 (en) 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
DE102010025663A1 (de) * 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
PH12013500275A1 (en) * 2010-08-10 2017-08-23 Abbvie Inc Novel trpv3 modulators
WO2012129491A1 (fr) 2011-03-24 2012-09-27 Abbott Laboratories Modulateurs de trpv3
WO2013062966A2 (fr) 2011-10-24 2013-05-02 Abbvie Inc. Nouveaux modulateurs de trpv3
CN106588812B (zh) * 2016-12-07 2019-02-22 烟台大学 一种酰氯制备2，4-二取代噻唑啉类化合物的方法
EP3911631B1 (fr) * 2019-01-14 2024-12-18 Zydus Lifesciences Limited Nouveaux dérivés de sulfonylurées substitués
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199549A (en) * 1878-01-22 Improvement in screw-propellers
US176694A (en) * 1876-04-25 Improvement in screw-cutting die-stocks
US23085A (en) * 1859-03-01 chandler
JPS5825980B2 (ja) * 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
EP0257701A1 (fr) 1986-08-15 1988-03-02 Cedona Pharmaceuticals B.V. Procédé pour la préparation de dérivés hydroxylés de composés contenant un groupement carbazole, dibenzofurane ou dibenzothiophène
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
AU662007B2 (en) * 1991-07-05 1995-08-17 Smithkline Beecham Farmaceutici S.P.A. Hydroisoquinoline derivatives
CN1043766C (zh) 1992-09-29 1999-06-23 东丽株式会社 吲哚衍生物及其制法和它们在制备药物中的应用
US5272146A (en) * 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP0848060A3 (fr) * 1996-12-11 2000-02-02 Smithkline Beecham Corporation Variante d'épissure de 11CB humaine
CN1117754C (zh) 1997-01-16 2003-08-13 东丽株式会社 吲哚并吗啡喃衍生物及其组合物
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1042498A4 (fr) 1997-12-03 2003-05-07 Smithkline Beecham Corp Procede de recherche d'un agoniste ou d'un antagoniste du variant d'epissage de 11 cb humain
EP1085869A4 (fr) 1998-06-11 2001-10-04 Merck & Co Inc Derives de spiropiperidine en tant qu'agonistes des recepteurs de la melanocortine
AU6035999A (en) 1998-09-17 2000-04-03 Incyte Pharmaceuticals, Inc. Human gpcr proteins
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
EP1143000B1 (fr) 1998-12-28 2007-02-14 Takeda Pharmaceutical Company Limited Methode d'analyse
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000049170A1 (fr) 1999-02-18 2000-08-24 Smithkline Beecham Corporation RECEPTEUR 11cby MURIN
EP1153932A1 (fr) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Nouvelle proteine de recepteur couplee a la proteine g et adn
CA2372980A1 (fr) 1999-05-19 2000-11-23 Astrazeneca Ab Dosages pour agonistes, antagonistes et agonistes inverses d'hormone concentrant la melanine (mch) se liant au recepteur du type somatostatine (slc-1)
AU5869100A (en) 1999-06-08 2000-12-28 Regents Of The University Of California, The Melanin concentrating hormone receptor
EP1200560A4 (fr) 1999-07-14 2003-06-11 Merck & Co Inc Recepteur d'hormone concentrant la melanine
CA2378403A1 (fr) 1999-07-26 2001-02-01 Genentech, Inc. Nouveaux polynucleotides et technique d'utilisation de ceux-ci
WO2001007606A1 (fr) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, recepteur couple g-proteine
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2001021169A1 (fr) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone de concentration de la melanine
EP1233981A4 (fr) 1999-11-16 2003-02-12 Merck & Co Inc Recepteur couple a la proteine g
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001068706A1 (fr) 2000-03-15 2001-09-20 Merck & Co., Inc. Proteines chimeres et de fusion du recepteur de l'hormone de concentration de la melanine
JP2005229804A (ja) 2000-03-24 2005-09-02 Astellas Pharma Inc 新規なメラニンコンセントレーティングホルモン受容体
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
EP1298439B1 (fr) 2000-07-05 2010-11-24 Takeda Pharmaceutical Company Limited Procede de criblage d'antagoniste/agoniste du recepteur de l'hormone de concentration de la melanine (mch)
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
EP1246847A2 (fr) 2000-07-05 2002-10-09 Synaptic Pharmaceutical Corporation Adn codant pour un recepteur humain de l'hormone de concentration de la melanine (mch1) et ses applications
US6569861B2 (en) 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
EP1326861A1 (fr) 2000-10-20 2003-07-16 Pfizer Products Inc. Ethanolamines alpha-aryle et utilisation de ces dernieres en tant qu'agonistes du recepteur adrenergique beta-3
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
MXPA03005744A (es) * 2000-12-22 2003-09-05 Schering Corp Antagonistas de piperidina mch y su uso en el tratamiento de obesidad.
US7034056B2 (en) 2001-03-21 2006-04-25 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
JP4280073B2 (ja) 2001-04-12 2009-06-17 ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
EP1392298B1 (fr) 2001-05-04 2009-02-18 Amgen Inc. Composes heterocycliques fondus
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6953801B2 (en) 2001-05-22 2005-10-11 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
IL161717A0 (en) * 2001-11-26 2004-09-27 Schering Corp Piperidine-based mch antagonists for treatment of obesity and cns disorders
JP2005532991A (ja) * 2002-01-10 2005-11-04 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ
AU2003285160B2 (en) * 2002-11-06 2009-06-04 Amgen Inc. Fused heterocyclic compounds

Also Published As

Publication number Publication date
JP4547266B2 (ja) 2010-09-22
US20040147538A1 (en) 2004-07-29
CA2505372A1 (fr) 2004-05-27
IS7833A (is) 2005-05-02
PL376659A1 (pl) 2006-01-09
US20080058365A1 (en) 2008-03-06
NO20052655D0 (no) 2005-06-02
US7253179B2 (en) 2007-08-07
AU2003285160B2 (en) 2009-06-04
EA009421B1 (ru) 2007-12-28
CN101134757A (zh) 2008-03-05
NZ540328A (en) 2008-02-29
AU2003285160A1 (en) 2004-06-03
EA200500770A1 (ru) 2005-12-29
KR20050103184A (ko) 2005-10-27
CN1330651C (zh) 2007-08-08
MXPA05004739A (es) 2005-08-02
CN1735613A (zh) 2006-02-15
ZA200503654B (en) 2006-09-27
EP1562943A1 (fr) 2005-08-17
BR0316070A (pt) 2005-09-27
JP2006508130A (ja) 2006-03-09
WO2004043958A1 (fr) 2004-05-27

Similar Documents

Publication Publication Date Title
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
WO2002089729A3 (fr) Composes heterocycliques fondus
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20055837L (no) Immunsupprimerende forbindelser og sammensetninger
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
WO2006012577A3 (fr) Derives de la quinazolinone utiles pour la regulation de l'homeostasie du glucose et de prise d'aliments
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
WO2005046603A3 (fr) Composes pyridiniques
WO2004009062A3 (fr) Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
DK1580188T3 (da) Forbindelser af arylurea som kinaseinhibitorer
WO2007079214A3 (fr) Antagonistes du recepteur de la prokineticine 2
NO20052655L (no) Sammensmeltede heterocykliske forbindelser
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
DK1694354T3 (da) Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
WO2007079163A3 (fr) Antagonistes du recepteur de la prokineticine 1
NO20073369L (no) Modulatorer av muskarinreseptorer
DE602005008412D1 (de) Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen
NO20056116L (no) Tiowolframatanaloger og anvendelse av slike

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application